INTRODUCTION: Accumulating evidence suggests that a-synuclein (aSyn) can modulate Alzheimer ' s disease (AD) pathology. The aim of this study was to evaluate the prevalence and clinical features associated with cerebrospinal fluid (CSF) aSyn detected by seed amplification assay (SAA) in AD.METHODS: Eighty AD patients with CSF AT(N) biomarker positivity (mean age 70.3 +/- 7.3 years) and 28 non-AD age-matched controls were included. All subjects underwent standardized clinical assessment; CSF aSyn aggregates were detected by SAA.RESULTS: CSF was aSyn-SAA positive (aSyn+) in 36/80 AD patients (45%) and in 2/28 controls (7.1%). AD aSyn+ and aSyn- patients were comparable for age, disease severity, comorbidity profile, and CSF core biomarkers. AD aSyn+ presented a higher prevalence of atypical phenotypes and symptoms.CONCLUSIONS: Our findings demonstrate that concomitant CSF aSyn pathology is present in a significant proportion of AD patients starting in the early stages and can affect clinical presentation. Longitudinal studies are warranted to evaluate the significance for the disease course.
CSF alpha-synuclein aggregates by seed amplification and clinical presentation of AD
Pilotto, Andrea;Tirloni, Clara;Galli, Alice;Padovani, Alessandro;
2023-01-01
Abstract
INTRODUCTION: Accumulating evidence suggests that a-synuclein (aSyn) can modulate Alzheimer ' s disease (AD) pathology. The aim of this study was to evaluate the prevalence and clinical features associated with cerebrospinal fluid (CSF) aSyn detected by seed amplification assay (SAA) in AD.METHODS: Eighty AD patients with CSF AT(N) biomarker positivity (mean age 70.3 +/- 7.3 years) and 28 non-AD age-matched controls were included. All subjects underwent standardized clinical assessment; CSF aSyn aggregates were detected by SAA.RESULTS: CSF was aSyn-SAA positive (aSyn+) in 36/80 AD patients (45%) and in 2/28 controls (7.1%). AD aSyn+ and aSyn- patients were comparable for age, disease severity, comorbidity profile, and CSF core biomarkers. AD aSyn+ presented a higher prevalence of atypical phenotypes and symptoms.CONCLUSIONS: Our findings demonstrate that concomitant CSF aSyn pathology is present in a significant proportion of AD patients starting in the early stages and can affect clinical presentation. Longitudinal studies are warranted to evaluate the significance for the disease course.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
